Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 3.56
MR's Cash to Debt is ranked higher than
59% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.41 vs. MR: 3.56 )
Ranked among companies with meaningful Cash to Debt only.
MR' s 10-Year Cash to Debt Range
Min: 0.65  Med: 6.49 Max: No Debt
Current: 3.56
Equity to Asset 0.64
MR's Equity to Asset is ranked higher than
61% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. MR: 0.64 )
Ranked among companies with meaningful Equity to Asset only.
MR' s 10-Year Equity to Asset Range
Min: 0.32  Med: 0.73 Max: 0.89
Current: 0.64
0.32
0.89
Interest Coverage 30.08
MR's Interest Coverage is ranked lower than
51% of the 105 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.02 vs. MR: 30.08 )
Ranked among companies with meaningful Interest Coverage only.
MR' s 10-Year Interest Coverage Range
Min: 17.97  Med: 50.20 Max: 9999.99
Current: 30.08
17.97
9999.99
F-Score: 5
Z-Score: 4.08
WACC vs ROIC
8.60%
19.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.45
MR's Operating margin (%) is ranked higher than
74% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.42 vs. MR: 14.45 )
Ranked among companies with meaningful Operating margin (%) only.
MR' s 10-Year Operating margin (%) Range
Min: 14.55  Med: 22.09 Max: 27.61
Current: 14.45
14.55
27.61
Net-margin (%) 14.27
MR's Net-margin (%) is ranked higher than
84% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.58 vs. MR: 14.27 )
Ranked among companies with meaningful Net-margin (%) only.
MR' s 10-Year Net-margin (%) Range
Min: 14.61  Med: 21.60 Max: 26.52
Current: 14.27
14.61
26.52
ROE (%) 12.47
MR's ROE (%) is ranked higher than
71% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.05 vs. MR: 12.47 )
Ranked among companies with meaningful ROE (%) only.
MR' s 10-Year ROE (%) Range
Min: 12.4  Med: 24.81 Max: 128.45
Current: 12.47
12.4
128.45
ROA (%) 8.04
MR's ROA (%) is ranked higher than
75% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. MR: 8.04 )
Ranked among companies with meaningful ROA (%) only.
MR' s 10-Year ROA (%) Range
Min: 7.77  Med: 17.64 Max: 85.21
Current: 8.04
7.77
85.21
ROC (Joel Greenblatt) (%) 56.80
MR's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.82 vs. MR: 56.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 57.62  Med: 73.83 Max: 262.34
Current: 56.8
57.62
262.34
Revenue Growth (3Y)(%) 14.50
MR's Revenue Growth (3Y)(%) is ranked higher than
84% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. MR: 14.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 14.5  Med: 40.40 Max: 55.3
Current: 14.5
14.5
55.3
EBITDA Growth (3Y)(%) 10.00
MR's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. MR: 10.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 23.00 Max: 62.4
Current: 10
0
62.4
EPS Growth (3Y)(%) 5.00
MR's EPS Growth (3Y)(%) is ranked higher than
52% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. MR: 5.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MR' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: 22.40 Max: 63
Current: 5
0
63
» MR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

MR Guru Trades in Q3 2014

Frank Sands 485,275 sh (+4.63%)
John Rogers 78,349 sh (+1.78%)
Matthews China Fund 950,168 sh (-4.81%)
Jim Simons 274,100 sh (-31.56%)
» More
Q4 2014

MR Guru Trades in Q4 2014

Caxton Associates 54,200 sh (New)
Jim Simons 927,300 sh (+238.31%)
Frank Sands 634,124 sh (+30.67%)
Frank Sands 634,124 sh (+30.67%)
John Rogers Sold Out
Matthews China Fund 667,668 sh (-29.73%)
» More
Q1 2015

MR Guru Trades in Q1 2015

James Barrow 17,789 sh (New)
Frank Sands 634,224 sh (+0.02%)
Caxton Associates Sold Out
Matthews China Fund 446,868 sh (-33.07%)
Jim Simons 511,800 sh (-44.81%)
» More
Q2 2015

MR Guru Trades in Q2 2015

Matthews China Fund Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 17.21
MR's P/E(ttm) is ranked higher than
81% of the 108 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.20 vs. MR: 17.21 )
Ranked among companies with meaningful P/E(ttm) only.
MR' s 10-Year P/E(ttm) Range
Min: 15.91  Med: 22.90 Max: 95.74
Current: 17.21
15.91
95.74
Forward P/E 13.18
MR's Forward P/E is ranked higher than
85% of the 74 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.03 vs. MR: 13.18 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 17.20
MR's PE(NRI) is ranked higher than
80% of the 110 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.60 vs. MR: 17.20 )
Ranked among companies with meaningful PE(NRI) only.
MR' s 10-Year PE(NRI) Range
Min: 15.92  Med: 22.92 Max: 96.12
Current: 17.2
15.92
96.12
P/B 2.06
MR's P/B is ranked higher than
64% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.85 vs. MR: 2.06 )
Ranked among companies with meaningful P/B only.
MR' s 10-Year P/B Range
Min: 1.95  Med: 3.50 Max: 13.61
Current: 2.06
1.95
13.61
P/S 2.44
MR's P/S is ranked higher than
57% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.84 vs. MR: 2.44 )
Ranked among companies with meaningful P/S only.
MR' s 10-Year P/S Range
Min: 2.32  Med: 4.34 Max: 25.03
Current: 2.44
2.32
25.03
PFCF 13.67
MR's PFCF is ranked higher than
92% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.29 vs. MR: 13.67 )
Ranked among companies with meaningful PFCF only.
MR' s 10-Year PFCF Range
Min: 12.99  Med: 22.79 Max: 145.36
Current: 13.67
12.99
145.36
POCF 9.35
MR's POCF is ranked higher than
86% of the 113 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.15 vs. MR: 9.35 )
Ranked among companies with meaningful POCF only.
MR' s 10-Year POCF Range
Min: 8.88  Med: 17.77 Max: 1294
Current: 9.35
8.88
1294
EV-to-EBIT 10.43
MR's EV-to-EBIT is ranked higher than
83% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.59 vs. MR: 10.43 )
Ranked among companies with meaningful EV-to-EBIT only.
MR' s 10-Year EV-to-EBIT Range
Min: 12.4  Med: 19.75 Max: 92.4
Current: 10.43
12.4
92.4
PEG 1.85
MR's PEG is ranked higher than
69% of the 65 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. MR: 1.85 )
Ranked among companies with meaningful PEG only.
MR' s 10-Year PEG Range
Min: 0.4  Med: 1.91 Max: 2.33
Current: 1.85
0.4
2.33
Shiller P/E 17.48
MR's Shiller P/E is ranked higher than
86% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.99 vs. MR: 17.48 )
Ranked among companies with meaningful Shiller P/E only.
MR' s 10-Year Shiller P/E Range
Min: 16.63  Med: 26.67 Max: 42.66
Current: 17.48
16.63
42.66
Current Ratio 2.83
MR's Current Ratio is ranked higher than
59% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. MR: 2.83 )
Ranked among companies with meaningful Current Ratio only.
MR' s 10-Year Current Ratio Range
Min: 1.52  Med: 3.31 Max: 6.71
Current: 2.83
1.52
6.71
Quick Ratio 2.52
MR's Quick Ratio is ranked higher than
71% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.63 vs. MR: 2.52 )
Ranked among companies with meaningful Quick Ratio only.
MR' s 10-Year Quick Ratio Range
Min: 1.28  Med: 2.96 Max: 6.24
Current: 2.52
1.28
6.24
Days Inventory 99.65
MR's Days Inventory is ranked higher than
70% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 129.36 vs. MR: 99.65 )
Ranked among companies with meaningful Days Inventory only.
MR' s 10-Year Days Inventory Range
Min: 49.37  Med: 80.48 Max: 95.28
Current: 99.65
49.37
95.28
Days Sales Outstanding 49.54
MR's Days Sales Outstanding is ranked higher than
73% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.83 vs. MR: 49.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
MR' s 10-Year Days Sales Outstanding Range
Min: 20.38  Med: 61.40 Max: 83.07
Current: 49.54
20.38
83.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.47
MR's Dividend Yield is ranked higher than
57% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.45 vs. MR: 1.47 )
Ranked among companies with meaningful Dividend Yield only.
MR' s 10-Year Dividend Yield Range
Min: 0.34  Med: 1.03 Max: 2.28
Current: 1.47
0.34
2.28
Dividend Payout 0.25
MR's Dividend Payout is ranked higher than
74% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.36 vs. MR: 0.25 )
Ranked among companies with meaningful Dividend Payout only.
MR' s 10-Year Dividend Payout Range
Min: 0.52  Med: 0.96 Max: 1.67
Current: 0.25
0.52
1.67
Dividend growth (3y) 18.60
MR's Dividend growth (3y) is ranked higher than
78% of the 54 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.10 vs. MR: 18.60 )
Ranked among companies with meaningful Dividend growth (3y) only.
MR' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 0.00 Max: 42.2
Current: 18.6
0
42.2
Yield on cost (5-Year) 5.44
MR's Yield on cost (5-Year) is ranked higher than
87% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.65 vs. MR: 5.44 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MR' s 10-Year Yield on cost (5-Year) Range
Min: 1.26  Med: 3.81 Max: 8.43
Current: 5.44
1.26
8.43

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.85
MR's Price/Net Cash is ranked lower than
51% of the 39 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 14.22 vs. MR: 14.85 )
Ranked among companies with meaningful Price/Net Cash only.
MR' s 10-Year Price/Net Cash Range
Min: 10.34  Med: 14.94 Max: 556.33
Current: 14.85
10.34
556.33
Price/Net Current Asset Value 5.06
MR's Price/Net Current Asset Value is ranked higher than
67% of the 100 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.96 vs. MR: 5.06 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MR' s 10-Year Price/Net Current Asset Value Range
Min: 4.63  Med: 7.11 Max: 46.21
Current: 5.06
4.63
46.21
Price/Tangible Book 2.95
MR's Price/Tangible Book is ranked higher than
59% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.31 vs. MR: 2.95 )
Ranked among companies with meaningful Price/Tangible Book only.
MR' s 10-Year Price/Tangible Book Range
Min: 2.79  Med: 4.94 Max: 16.44
Current: 2.95
2.79
16.44
Price/Projected FCF 0.97
MR's Price/Projected FCF is ranked higher than
82% of the 79 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. MR: 0.97 )
Ranked among companies with meaningful Price/Projected FCF only.
MR' s 10-Year Price/Projected FCF Range
Min: 0.93  Med: 2.67 Max: 8.67
Current: 0.97
0.93
8.67
Price/DCF (Earnings Based) 0.60
MR's Price/DCF (Earnings Based) is ranked higher than
89% of the 18 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.75 vs. MR: 0.60 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.56
MR's Price/Median PS Value is ranked higher than
92% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.27 vs. MR: 0.56 )
Ranked among companies with meaningful Price/Median PS Value only.
MR' s 10-Year Price/Median PS Value Range
Min: 0.54  Med: 0.98 Max: 4.16
Current: 0.56
0.54
4.16
Price/Peter Lynch Fair Value 1.99
MR's Price/Peter Lynch Fair Value is ranked lower than
54% of the 41 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.98 vs. MR: 1.99 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.7  Med: 1.89 Max: 2.17
Current: 1.99
0.7
2.17
Price/Graham Number 1.47
MR's Price/Graham Number is ranked higher than
75% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. MR: 1.47 )
Ranked among companies with meaningful Price/Graham Number only.
MR' s 10-Year Price/Graham Number Range
Min: 1.39  Med: 2.22 Max: 6.54
Current: 1.47
1.39
6.54
Earnings Yield (Greenblatt) (%) 9.59
MR's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. MR: 9.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.1  Med: 5.10 Max: 9.59
Current: 9.59
1.1
9.59
Forward Rate of Return (Yacktman) (%) 13.96
MR's Forward Rate of Return (Yacktman) (%) is ranked higher than
58% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.94 vs. MR: 13.96 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MR' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 0.7  Med: 13.10 Max: 48
Current: 13.96
0.7
48

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:MRN.Mexico, K3QD.Singapore, G2N.Germany,
Mindray Medical International Ltd was incorporated as an exempted company with limited liability in the Cayman Islands on June 10, 2005 under the Companies Law of the Cayman Islands. The Company is a developer, manufacturer and marketer of medical devices worldwide. The Company operates three primary business segments: patient monitoring and life support products, in-vitro diagnostic products, and medical imaging systems. The Company's patient monitoring devices track the physiological parameters of patients, such as heart rate, blood pressure, respiration and temperature. It currently offers patient monitoring devices that are suitable for adult, pediatric and neonatal patients and are used principally in hospital intensive care units, operating rooms and emergency rooms. Its product line offers customers functionality, such as single- and multiple-parameter monitors, mobile and portable multifunction monitors, central stations that can collect and display multiple patient data on a single screen, and an electro-cardiogram monitoring device. Its multi-parameter monitoring devices can be networked, allowing hospitals to remotely gather patient data from patient rooms and centralize that data in a single location. Its patient monitoring devices also have built-in recorders and have batteries for portability in models, as well as power backup in the event of power failure in mobile models. It also offers a line of veterinary monitoring devices. The Life support products offers anesthesia machines, defibrillators, surgical equipment (including surgical beds and surgical lights ceiling pendants), syringes and infusion pumps, as well as ventilators. The in-vitro diagnostic products provide data and analysis on blood, urine and other bodily fluid samples for clinical diagnosis and treatment. It offers a range of semi-automated and fully-automated in-vitro diagnostic products for laboratories, clinics and hospitals to perform analysis to detect and quantify various substances in the patient samples. Its current product portfolio consists of in-vitro diagnostic products in six product categories: hematology analysis products, biochemistry analysis products, immunoassay products, coagulation analysis products, urine sediment analysis products, and microbiology analysis products. The hematology analyzers test blood samples to detect abnormalities or foreign substances. The biochemistry analyzers measure the concentration or activity of substances such as enzymes, proteins and substrates. The immunoassay analyzers measure the concentration of protein such as hormone, tumor marker and virus protein. The coagulation analyzers are used to measure activated partial thromboplastin time (APPT), prothrombin time (PT), thrombin time (TT), fibrinogen (FIB), D-Dimer and clotting factor. Urinalysis includes urine sediment and dry chemistry analysis. Urinalysis, together with hematology and biochemistry analysis, are the three common methods used in in
» More Articles for MR

Headlines

Articles On GuruFocus.com
Matthews China Fund's Top Second Quarter Holdings Jul 31 2014 
Guru Held International Stocks Near 52-Week Lows Jul 31 2014 
Morning Coffee: Widely Held International Guru Stocks Near 52-Week Lows May 16 2014 
The Matthews China Fund's Top Five Fourth Quarter Holdings Feb 04 2014 
12 Healthcare Dividend Stocks With Highest Short Float Ratio Jun 02 2012 
value May 05 2012 
12 Healthcare Dividend Stocks with Gaining Earnings Momentum Apr 02 2012 
5 Mid-Cap Healthcare Dividend Stocks with Perfect Earnings Growth Dec 05 2011 
growth,high ROA,medi Oct 29 2011 
100 Best Growth Stocks – Part VII May 12 2011 

More From Other Websites
Mindray to Report 2015 Second Quarter Financial Results on August 10, 2015 Jul 21 2015
Mindray to Report 2015 Second Quarter Financial Results on August 10, 2015 Jul 21 2015
Mindray Medical Completes Acquisition of Wuhan Dragonbio Jul 17 2015
Mindray Medical Completes Acquisition of Wuhan Dragonbio Jul 17 2015
China Stock Roundup: Mindray Medical to Buy Remaining Stake in Dragonbio, Noah Holdings Announces... Jul 09 2015
Mindray Medical to Acquire Remaining Stake in Dragonbio - Analyst Blog Jul 08 2015
Mindray Medical (MR) in Focus: Stock Falls 5.2% in Session - Tale of the Tape Jul 07 2015
Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio Jul 07 2015
Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio Jul 07 2015
Mindray Medical's New Committee to Study Going Private Plan - Analyst Blog Jun 25 2015
Mindray Announces Formation of a Special Committee to Evaluate "Going Private" Proposal Jun 24 2015
Mindray Announces Formation of a Special Committee to Evaluate "Going Private" Proposal Jun 24 2015
Chinese tech firm Qihoo gets $9B buyout offer from CEO Jun 18 2015
Chinese tech firm Qihoo gets $9B buyout offer from CEO Jun 18 2015
China Stock Roundup: Yingli Green, LightInTheBox Earnings Disappoint - Analyst Blog Jun 12 2015
Going-Private Bids Flood in for Chinese Firms Languishing on U.S. Exchanges Jun 11 2015
Mindray Medical upgraded by JMP Securities Jun 05 2015
Mindray: Don't Expect A Sweeter Deal, Says Deutsche Jun 04 2015
Mindray Rallies on Buyout Offer for Chinese Medical Device Maker Jun 04 2015
Mindray Medical (MR) Stock Gains After Receiving 'Going Private' Proposal Jun 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK